Convatec Group PLC

CTEC: XLON (GBR)
View Stock Summary
Morningstar Rating for StocksFair ValueEconomic MoatCapital Allocation
QD^LOCK|?!h<RLOCK|PHJD>lN

Convatec Earnings: Cuts to Innovamatrix Reimbursement Hampers Growth in 2025

Convatec delivered full-year consolidated revenue growth of 5%, dragged down by declines in Innovamatrix skin substitute. But, the remainder of the portfolio grew 6% with ostomy, continence care, and infusion therapy up 5%, 7%, and 13%, respectively.

Sponsor Center